Vigonvita Life Sciences Co., Ltd.
Research Vigonvita Life Sciences Co., Ltd. (2630.HK) on Bullrun: market cap HKD 13.41B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker2630.HK
- ExchangeHK
- CountryChina
- SectorHealthcare
- IndustryDrug Manufacturers - General
- CurrencyHKD
- Market capHKD 13.41B
- Financial periodFY2025
- RevenueCNY 102.10M
- Net income-CNY 355.72M
- Free cash flow-CNY 260.48M
- Gross margin79.0%
Valuation Snapshot
latest market cap is HKD 13.41B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CNY 102.10M | -CNY 355.72M | -CNY 260.48M | 79.0% | -2.33 | CNY 447.97M | CNY 646.57M | CNY 446.22M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | HKD 13.41B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 HKD.
About Vigonvita Life Sciences Co., Ltd.
Vigonvita Life Sciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule drugs for neuropsychiatry, reproductive health, and viral infection therapeutic areas. Its products include LV232, a first-in-class dual-target 5-HTT/5-HT modulators, which is in Phase II of clinical trial for the treatment of depressive disorder; and TPN171, a type-5 phosphodiesterase inhibitor completed Phase III clinical trial for the treatment of erectile dysfunction.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Vigonvita Life Sciences Co., Ltd.'s market cap?
Vigonvita Life Sciences Co., Ltd.'s market capitalization is HKD 13.41B.
What does Vigonvita Life Sciences Co., Ltd. do?
Vigonvita Life Sciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule drugs for neuropsychiatry, reproductive health, and viral infection therapeutic areas. Its products include LV232, a first-in-class dual-target 5-HTT/5-HT modulators, which is in Phase II of clinical trial for the treatment of depressive disorder; and TPN171, a type-5 phosphodiesterase inhibitor completed Phase III clinical trial for the treatment of erectile dysfunction.